Collaboration and License Arrangements - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Collaboration And License Arrangement [Line Items]
Revenue from license agreement	$ 365	$ 844	$ 784	$ 1,796
Contract asset	4,764		4,764		$ 4,537
Other Liabilities [Member]
Collaboration And License Arrangement [Line Items]
Cash received for milestone payment	15,000		$ 15,000		$ 15,000
EQRx, Inc [Member]
Collaboration And License Arrangement [Line Items]
Collaborative arrangement, rights and obligations			During the three and six months ended June 30, 2022, there were no changes to the Company’s Discovery and Collaboration Agreement (“Collaboration Agreement”) with EQRx, Inc. (“EQRx”) from August 2021. Accordingly, there were no changes to the Company’s accounting treatment thereon through June 30, 2022.
Genentech [Member]
Collaboration And License Arrangement [Line Items]
Collaborative arrangement, rights and obligations			During the three and six months ended June 30, 2022 and 2021, there were no material changes to the Company’s Collaboration and License Agreement (“License Agreement”) with Genentech, Inc. (“Genentech”) from December 2020. Accordingly, there were no changes to the Company’s accounting treatment thereon through June 30, 2022.
Genentech [Member] | License Agreement [Member]
Collaboration And License Arrangement [Line Items]
Revenue from license agreement	$ 300	$ 800	$ 500	$ 1,700